Hepatocellular carcinoma is highly refractory cancer which is resistant to conventional chemotherapy and radiotherapy, carrying a dismal prognosis. Although many anticancer drugs have been developed for treating HCC, sorafenib is the only effective treatment, but it only prolongs survival duration for about 3 months. Recently, oncolytic virotherapy has shown promising results in treating HCCs and the effects can be more enhanced by adopting immune modulatory molecules. This review discusses the current status of treating HCC and the effective strategy of oncolytic virus-based immunotherapy for the treatment of HCCs.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2oR6PWG
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Objectives Greece is one of the leading tobacco-producing countries in European Union, and every year over 19 000 Greeks die from tobacco-at...
-
Objectives Drug interactions, poor adherence to medication and high-risk sexual behaviour may occur in individuals with HIV using recreation...
-
Abstract Background Mature T-cell and natural killer (NK)-cell lymphomas compose a heterogeneous group of non-Hodgkin lymphomas, and ext...
-
Introduction Multimorbidity (MM) refers to the coexistence of two or more chronic conditions within one person, where no one condition is co...
-
Objective To describe the prevalence and severity of diabetic retinopathy (DR) and sight-threatening DR (STDR) among Chinese adults with dia...
-
Related Articles Three job stress models and their relationship with musculoskeletal pain in blue- and white-collar workers. J Psycho...
-
<span class="paragraphSection"><div class="boxTitle">Abstract</div>Masked hypertension (MHT), defined ...
-
Background Hepatitis B virus (HBV) transmission is known to occur through direct contact with infected blood. There has been some suspicion ...
-
In Rwanda, the prevalence of viral hepatitis (HCV) is poorly understood. The current study investigated the prevalence and risk factors of H...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου